Bristol-Myers, Acceleron's Reblozyl Ok'd In Canada For MDS-Associated Anemia

by Vandana Singh, Benzinga Editor

February 16, 2021 12:13 PM | 1 min read |

Bristol-Myers Squibb Co (NYSE: BMY) and its collaborating partner Acceleron Pharma Inc (NASDAQ: XLRN) have announced that Health Canada has approved Reblozyl (luspatercept for injection) to treat anemia in myelodysplastic syndromes (MDS) patients with ring sideroblasts.
It is a low-risk subtype of blood cancer in which red blood cells contain a ring of excess iron.
The approval is limited to those who require regular red blood cell transfusion and have failed an erythropoietin-based therapy.
The treatment received FDA approval in April last year for the same indication. In Europe, the med was approved in June last year.
Price Action: BMY shares are down 0.50% at $59.69, and XLRN shares are down 3.21% at $126.65 on last check Tuesday.

Posted In: Biotech News Health Care FDA General Anemia

Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.